Clinical Trials | December 07, 2025
Bayer reports promising results for low-dose pediatric MRI contrast agent
MRI is particularly valuable in pediatric care due to its non-invasive nature
MRI is particularly valuable in pediatric care due to its non-invasive nature
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
The complexity of operating on a one-year-old are many with the organs being tiny, fragile
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
Subscribe To Our Newsletter & Stay Updated
